Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 24, 2024

BUY
$356.95 - $413.29 $25,343 - $29,343
71 Added 0.67%
10,742 $4.23 Million
Q4 2023

Feb 08, 2024

SELL
$338.91 - $506.01 $582,586 - $869,831
-1,719 Reduced 13.87%
10,671 $4.06 Million
Q3 2023

Oct 24, 2023

SELL
$369.35 - $548.43 $57,249 - $85,006
-155 Reduced 1.24%
12,390 $6.09 Million
Q2 2023

Jul 31, 2023

BUY
$360.14 - $422.58 $54,021 - $63,387
150 Added 1.21%
12,545 $4.89 Million
Q1 2023

May 08, 2023

SELL
$334.23 - $403.65 $93,584 - $113,022
-280 Reduced 2.21%
12,395 $4.62 Million
Q4 2022

Feb 13, 2023

SELL
$342.17 - $402.31 $205,986 - $242,190
-602 Reduced 4.53%
12,675 $4.8 Million
Q3 2022

Nov 14, 2022

SELL
$343.2 - $395.75 $284,512 - $328,076
-829 Reduced 5.88%
13,277 $4.69 Million
Q2 2022

Nov 14, 2022

SELL
$269.58 - $378.88 $515,167 - $724,039
-1,911 Reduced 11.93%
14,106 $5.35 Million
Q2 2022

Sep 13, 2022

BUY
$269.58 - $378.88 $442,380 - $621,742
1,641 Added 12.21%
15,086 $5.72 Million
Q2 2022

Aug 02, 2022

SELL
$269.58 - $378.88 $1.03 Million - $1.45 Million
-3,824 Reduced 22.14%
13,445 $5.09 Million
Q1 2022

Nov 14, 2022

BUY
$254.45 - $351.06 $236,892 - $326,836
931 Added 6.17%
16,017 $5.05 Million
Q1 2022

Sep 13, 2022

BUY
$254.45 - $351.06 $414,244 - $571,525
1,628 Added 10.41%
17,269 $5.45 Million
Q1 2022

May 09, 2022

BUY
$254.45 - $351.06 $1.6 Million - $2.21 Million
6,292 Added 67.3%
15,641 $4.93 Million
Q4 2021

Jan 27, 2022

BUY
$272.01 - $353.03 $2.54 Million - $3.3 Million
9,349 New
9,349 $3.27 Million
Q2 2019

Aug 12, 2019

SELL
$115.0 - $141.58 $681,145 - $838,578
-5,923 Closed
0 $0
Q1 2019

May 15, 2019

BUY
$98.85 - $134.59 $585,488 - $797,176
5,923 New
5,923 $739,000

Others Institutions Holding ARGX

About ARGENX SE


  • Ticker ARGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,323,800
  • Market Cap $31.2B
  • Description
  • argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...
More about ARGX
Track This Portfolio

Track Brown Advisory Inc Portfolio

Follow Brown Advisory Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Brown Advisory Inc, based on Form 13F filings with the SEC.

News

Stay updated on Brown Advisory Inc with notifications on news.